PB1958: IBRUTINIB AS THIRD LINE THERAPY IN CLL PATIENTS, A 5-YEAR STUDY IN ALBANIA

Detalles Bibliográficos
Autores principales: Qerama, Shaqir, Seraj, Liri, Kociaj, Jora, Buhaljoti, Lorena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430128/
http://dx.doi.org/10.1097/01.HS9.0000974648.23994.7c
_version_ 1785090881703903232
author Qerama, Shaqir
Seraj, Liri
Kociaj, Jora
Buhaljoti, Lorena
author_facet Qerama, Shaqir
Seraj, Liri
Kociaj, Jora
Buhaljoti, Lorena
author_sort Qerama, Shaqir
collection PubMed
description
format Online
Article
Text
id pubmed-10430128
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-104301282023-08-17 PB1958: IBRUTINIB AS THIRD LINE THERAPY IN CLL PATIENTS, A 5-YEAR STUDY IN ALBANIA Qerama, Shaqir Seraj, Liri Kociaj, Jora Buhaljoti, Lorena Hemasphere Publication Only Lippincott Williams & Wilkins 2023-08-08 /pmc/articles/PMC10430128/ http://dx.doi.org/10.1097/01.HS9.0000974648.23994.7c Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially.
spellingShingle Publication Only
Qerama, Shaqir
Seraj, Liri
Kociaj, Jora
Buhaljoti, Lorena
PB1958: IBRUTINIB AS THIRD LINE THERAPY IN CLL PATIENTS, A 5-YEAR STUDY IN ALBANIA
title PB1958: IBRUTINIB AS THIRD LINE THERAPY IN CLL PATIENTS, A 5-YEAR STUDY IN ALBANIA
title_full PB1958: IBRUTINIB AS THIRD LINE THERAPY IN CLL PATIENTS, A 5-YEAR STUDY IN ALBANIA
title_fullStr PB1958: IBRUTINIB AS THIRD LINE THERAPY IN CLL PATIENTS, A 5-YEAR STUDY IN ALBANIA
title_full_unstemmed PB1958: IBRUTINIB AS THIRD LINE THERAPY IN CLL PATIENTS, A 5-YEAR STUDY IN ALBANIA
title_short PB1958: IBRUTINIB AS THIRD LINE THERAPY IN CLL PATIENTS, A 5-YEAR STUDY IN ALBANIA
title_sort pb1958: ibrutinib as third line therapy in cll patients, a 5-year study in albania
topic Publication Only
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430128/
http://dx.doi.org/10.1097/01.HS9.0000974648.23994.7c
work_keys_str_mv AT qeramashaqir pb1958ibrutinibasthirdlinetherapyincllpatientsa5yearstudyinalbania
AT serajliri pb1958ibrutinibasthirdlinetherapyincllpatientsa5yearstudyinalbania
AT kociajjora pb1958ibrutinibasthirdlinetherapyincllpatientsa5yearstudyinalbania
AT buhaljotilorena pb1958ibrutinibasthirdlinetherapyincllpatientsa5yearstudyinalbania